about
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugsGenotyping panel for assessing response to cancer chemotherapy.Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyPolymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Identification of genes in HepG2 cells that respond to DNA methylation and histone deacetylation inhibitor treatmentKey Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.Contribution of tumoral and host solute carriers to clinical drug response.Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in miceGSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.Pharmacogenetics of drug transporters in the enterohepatic circulation.Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradationsSingle nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.Obstacles to Brain Tumor Therapy: Key ABC Transporters.The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens.
P2860
Q21245491-2FAA124E-1E6B-4037-BDA9-8B963272A280Q33343095-F618201E-E328-4525-8D9F-E28A739E161FQ33382930-9A32C0FF-B1AC-421A-B233-BD8A07600E49Q33434697-313085F5-F87F-47D7-83E1-D35D02A27155Q33962216-615AD910-34AE-463E-8223-A755EE7037DBQ34415050-883A8BE8-D2D3-44B7-81C6-41669E5F7424Q34681466-CFA0B539-B9C3-42EB-9DCA-EF257107A840Q35171432-7879D652-0A8B-4FC8-B918-6746BCD2F63CQ35946876-D86C63D2-D978-4F33-A4C6-A100989DCDB9Q36043023-FA563128-75D7-4CAE-BA8D-3A11FC062ABCQ36441493-3F4B66AB-5668-4CD7-B0EA-AF11E5082423Q36599618-399A9C3E-F5F0-4F01-BC11-2DDB5A98339AQ36943992-2C8EA373-74C9-4C9F-8890-B831E79115C4Q37880875-8B7A8D0D-D866-40B4-806E-48CDBB3E359EQ38981028-760FFA34-0AD3-4870-B137-1A7141A574D5Q39923958-8C41363B-A285-46F8-9353-1C476E47B7F4Q43288450-B2DCEB56-6C38-4972-A2EB-381688296D5AQ47944360-F4C12C71-0FF9-412E-BE78-DF1C7523FFB1Q48027272-AF50CA7D-3E4C-412B-AC35-BC326BB68910Q53816469-7396EBC3-2347-4CDD-8412-9010E2DC7DDA
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Role of pharmacogenetics in irinotecan therapy.
@ast
Role of pharmacogenetics in irinotecan therapy.
@en
type
label
Role of pharmacogenetics in irinotecan therapy.
@ast
Role of pharmacogenetics in irinotecan therapy.
@en
prefLabel
Role of pharmacogenetics in irinotecan therapy.
@ast
Role of pharmacogenetics in irinotecan therapy.
@en
P2093
P1433
P1476
Role of pharmacogenetics in irinotecan therapy.
@en
P2093
Floris A de Jong
Jaap Verweij
Maja J A de Jonge
Ron H J Mathijssen
P304
P356
10.1016/J.CANLET.2005.04.040
P407
P577
2005-12-15T00:00:00Z